Hefcard 200 Tablet contains a combination of Sacubitril 97 mg and Valsartan 103 mg, formulated for the management of heart failure. Sacubitril is a neprilysin inhibitor that enhances the levels of natriuretic peptides, promoting vasodilation, natriuresis, and diuresis, thereby reducing cardiac workload. Valsartan, an angiotensin II receptor blocker (ARB), inhibits the effects of angiotensin II, leading to vasodilation, decreased aldosterone secretion, and reduced blood pressure. The synergistic action of these agents helps improve cardiac function and reduce the risk of hospitalization and mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF). Hefcard 200 is indicated for patients who remain symptomatic despite optimal standard therapy. It is essential to initiate treatment under medical supervision, with appropriate monitoring of renal function, electrolytes, and blood pressure. Contraindications include a history of angioedema related to previous ACE inhibitor or ARB therapy, pregnancy, and severe hepatic impairment. Common adverse effects may include hypotension, hyperkalemia, dizziness, and renal impairment. Dose adjustments may be necessary in patients with renal or hepatic dysfunction. Hefcard 200 should be used cautiously in combination with other agents affecting the renin-angiotensin-aldosterone system to minimize the risk of adverse events.